Forget what you heard before late 2022. That’s the pivot point. Before ChatGPT went public, medical AI was rigid. It was “narrow AI” — good at one specific, repetitive task, terrible at everything else.
Developers trained these models on labeled data. Think mammograms. Feed an algorithm thousands of images, clearly marked as “cancer” or “benign,” and it learns to spot the difference. It spits out a risk score for new images. It works. In fact, a big Nature study showed AI beating average radiologists, cutting false positives and negatives significantly in U.S. datasets.
But narrow AI has a blind spot.
A tool that reads breasts cannot read lungs. It can’t find a broken rib, even if the rib is sitting right next to the lung. It’s useful, yes. The FDA has authorized over 1,500 such devices. Yet adoption in daily practice? Slothful. High cost, weird reimbursement rules, and the terrifying shadow of liability keep these tools on the shelf.
Then came the big shift. Generative AI.
Instead of narrow tasks, these models drink the ocean of text. Textbooks. Research papers. Every medical fact online. This foundation lets them handle the messy, broad reality of being human. Explain an X-ray. Assess vague symptoms. Manage chronic illness. Break down side effects. Crucially, anyone can use them. Patients, not just doctors.
OpenAI found that 55% of adults already check their symptoms on ChatGPT. They are doing it anyway.
“The commercial use of medical AI remains stuck in administrative tasks, ignoring the massive potential for patient-facing care.”
Hospitals mostly use GenAI to do paperwork. Microsoft’s Dragon Copilot listens to conversations and writes notes. Other tools fix billing codes to stop claim denials. Efficient. Profitable for insurers.
Almost zero apps are built for the patient to use alone.
Why? Because building a medical-grade narrow AI is expensive. Data acquisition. Validation. FDA approval. It costs millions, which means the price tag is too high for regular people. Plus, liability. If an AI misses a cancer diagnosis and sells directly to you, you sue the company. If it sells to the hospital, the doctor is the ultimate decision maker. The legal risk vanishes for the maker.
That makes a recent NYU study explosive.
They compared expensive, specialized clinical tools against cheap, general-purpose Large Language Models (LLMs). The result? The branded, “medical” tools had no edge. The free or cheap LLMs performed as well or better.
This changes everything. General LLMs don’t diagnose specific diseases, so they don’t trigger strict FDA review. No FDA review means fewer lawsuits. Fewer barriers mean entrepreneurial freedom.
The Next Healthcare Unicorn
Here is the opportunity. Don’t build another expensive, single-task medical device. There’s no money there.
Help people use the existing GenAI. That’s the next healthcare giant.
The path isn’t smooth. Entrepreneurs will face hard questions. Will it be an app? A suite of agents? An educational platform? How do you make money — subscriptions? Employer contracts? Performance-based rewards?
Safety is the nightmare. Accuracy depends on how the user phrases questions. Follow-ups matter. What happens when the AI flags a real medical crisis at 3 AM? You need 24/7 clinical support infrastructure, or you are liable.
It is complex. It is risky.
But the logic holds up. Treat a patient in a clinic, you help them for an hour. Teach a patient to wield AI effectively, you improve their health management for decades.
The market is wide open. Who will jump in first?
